PRALUZATAMAB
UNII X7F47LV4T7

Substance Identification & Data

This profile provides standardized clinical and technical data for Praluzatamab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) X7F47LV4T7.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2145109-70-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

X7F47LV4T7

CAS Registry Number

2145109-70-0

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

PRALUZATAMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C174944

National Cancer Institute reference terminology for clinical and research data.

INN ID

10940

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

HI-168

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Praluzatamab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

PRALUZATAMAB

Common Names & Synonyms

ANTI-CD166 PROBODY-DRUG

CX-191

IMMUNOGLOBULIN G1, ANTI-(HUMAN ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE) (HUMAN MONOCLONAL CX-191 .GAMMA.1-CHAIN), DISULFIDE WITH PRODOMAIN PROTEIN (SYNTHETIC MASKING MOIETY AND CLEAVABLE MOIETY PROTEASE SUBSTRATE-CONTAINING) FUSION PROTEIN WITH HUMAN MONOCLONAL CX-191 .KAPPA.-CHAIN, DIMER

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD166 (ACTIVATED LEUCOCYTE CELL ADHESION MOLECULE, ALCAM)), HUMANIZED MONOCLONAL ANTIBODY

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD166 ANTIGEN (ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE)); HUMANIZED MONOCLONAL ANTIBODY; .GAMMA.1 HEAVY CHAIN HUMANIZED (1-450) (VH (HOMO SAPIENS IGHV2-5*01 (89%) (IGHD)-IGHJ4*01 (93%)) (10.7.13) (1-121)-HOMO SAPIENS IGHG1*03 (CH1(R97>K(217)), CH3(K107>DEL(451))) (122-450)), (224-270')-DISULFIDE WITH .KAPPA. LIGHT CHAIN HUMANIZED (1'-270') (N-TERMINAL REGION (SYNTHETIC MASKING MOIETY-(1'-22')-TRIGLYCYLDISERYLDIGLYCYLSERYL LINKER-(23'-30')-CLEAVABLE MOIETY PROTEASE SUBSTRATE-CONTAINING-(31'-48')-DIGLYCYLSERYL LINKER (49'-51')))-(1'-51')-(HUMANIZED V-KAPPA (MUS MUSCULUS IGKV2-109*01 (91%) IGKJ2*03 (92%):HOMO SAPIENS IGKV2-28*01 (89%) IGKJ2*01)-(11.3.9) (52'-163')-HOMO SAPIENS IGKC*01 (164'-270')), DIMER (230-230'':233-233'')-BISDISULFIDE

PRALUZATAMAB [INN]

PRALUZATAMAB [USAN]

External Clinical & Regulatory Resources

Previous UNIIX7F43HL2HB

Next UNIIX7FNK5MFIE